B5.027 - Hepatitis Viruses Flashcards

(36 cards)

1
Q

describe HAV

A

picornoviridae HAV aka enterovirus 72 small (27nm) non enveloped ssRNA (+) replication exclusively in cytoplasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

HAV typical serologic course

A

1-2 months after exposure - fecal HAV, ALT rises total anti HAV develops after 2-4 months, stays for life IgM starts after 1 month, drops around 4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

is there a vaccine for HAV?

A

yes, greatly reduced incidence after 1995

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

incubation period, jaundice by age group, complications/clinical sequelae of HAV

A

avg 30 days 6-14 yo - 40-50% >14 yo - 70-80% fulminant hepatitis cholestatic hepatitis relapsing hepatitis no clinical sequelae

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

HAV vaccine

A

inactivated vaccine adsorbed onto aluminum hydroxide 94-100% effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what types of enveloped proteins does HBV have

A

small, medium and large

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what role does the large protein have

A

has receptor binding site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what proteins does HBV need to make it infectious

A

small and large proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

why does HBV need small particles

A

to ensure release of proteins from cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

possible mechanisms of HBV induced liver carcinogenesis

A
  1. integration of HBV DNA into host DNA leading to genome instability and mutations 2. DNA damage from chronic infection 3. X protein acts as transcription activator 4. persistent liver damage resulting in hepatocyte proliferation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

treatment of HBV in order of use

A
  1. tenofovir 2. entecavir 3. telbivudine 4. adefovir 5. lamivudine 6. Pegylated IFN 7. IFN alpha
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

first line treatment of HBV

A

tenofovir entecavir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

describe labs for HBV

A

HBsAg - surface angigen, marker of infectivity when found in serum anti-HBsAg - antibody to HBsAg, marker of immunity anti-HBcAg - marker of past or current infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is IgM anti-HBc

A

antibody indicating recent infection with HBV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

IgG anti HBc

A

IgG is a subclass of anti HBc indicates older infection with HBV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is HBeAg

A

Hepatitis B e antigen can only be present if HBsAg is positive. Indicates active infection

17
Q

what is anti HBe

A

antibody to e antigen may be present in infected or immune person

18
Q
A

susceptible to HBV infection

19
Q

HBsAg neg

Anti HBc pos

Anti HBs pos

A

immune to natural infection

20
Q

HBsAg neg

Anti HBc neg

AntiHBs pos

A

immune due to vaccine

21
Q

HBsAg pos

AntiHBc pos

IgM antiHBc pos

anti HBs neg

A

acutely infected

22
Q

HBsAg pos

anti HBc pos

IgM antiHBc neg

anti HBs neg

A

chronically infected

23
Q

HBsAg neg

IgM anti HBc pos

anti HBs neg

A
  1. resolved HBV infection
  2. may be susceptible with a false positive anti HBc
  3. may have low level chronic infection
  4. may be resolving an acute infection
24
Q

describe the two types of HDV infection

A

coinfection with HBV

Superinfection (ad different times)

25
outcomes of coinfection
3-4% fulminate hepatitis --\> death 90% - acute severe disease --\> recovery 5% - crhonic --\> cirrhosis
26
superinfection outcomes
5% - fulminate hepatitis --\> death 10-15% acute severe disease --\> recovery 80% - chronic hepatitis --\> cirrhosis
27
HCV incubation period, acute illness, case fatality rate from acute infx
6-7 wks mild \<20% low
28
current treatment of HCV
ledipasvir and sofosbuvir
29
describe the developement of HCV associated HCC
viral entry and replication inflammation, cellular growth signals, resistance to apoptosis, oxidative stress, metabolic disorders fibrogenesis, hypoxia, genetic instability, LPS translocation from intestinal microbiota
30
incidence of HCC in different hepatitis
HBV - 60% HCV - 25% neither - 12% both - 3%
31
host of the four types of HEV
1 - humans and pigs 2 - humans 3 - humans and animals
32
route of admin of 4 types of HEV
1, 2 - fecal oral, vertical 3, 4 - zootonic usually swine, environmental and blood transfusion
33
geographical distribution of the 4 types of HEV
1 - mainly asia 2 - MX and west africa 3 - worldwide 4 - china, east asia, central europe, america
34
seasonality of types of HEV
1,2, - flooding/monsoon season 3,4 - no
35
clinical presentation of HEV types
1,2 - acute self limited hepatitis 3,4 - may lead to chronocity in immunosuppressed (3)
36
prognosis/chronic infection of HEV types
1 - high mortality in pregnancy 2 - fulminant hepatitis not noted, no chronic 3, 4 - higher overall mortality relative to 1, and in older adutls, yes chronic